The study is a single arm, retrospective cohort study of patients with a deleterious, suspected

deleterious, or pathogenic germline BRCA1/2 or PALB2 mutation breast cancer.

Treatment pattern with Talazoparib, discontinuation due to disease progression, unacceptable toxicity,

consent withdrawal or physician discretion will be studied.

Patients who were discontinued from study medication for any reason other than radiographic disease

progression as determined by the IRF or initiation of a new antineoplastic therapy will be followed to

radiographic progression by imaging assessments (eg, computed tomography [CT] scans).

Patients with altleast one available medical record on EMR will be included in the analysis.

Progression free survival, overall survival and toxicity will be studied.

Response will be assessed post evaluation of age, menopausal status, baseline tumor characteristics,

ECOG, metastatic sites, comorbidities, previous anticancer treatment like surgery, radiation,

chemotherapy lines received, ET lines, other ongoing treatments for comorbidities, visceral, non

visceral disease.

Data will be collected through EMR from all available records and reports such as blood

investigations, radiological reports, physician notes and histopathological reports to assess the

primary objective of the trial. Response will be calculated from the day of starting of Talazoparib to

date of last dose. Toxicity will be graded as per CTCAE V 4.03. Adverse events and tolerability will

be assessed along with time to recover from the toxicity. Dose reductions and interruptions will be

studied.